CD1C and systemic lupus erythematosus: These results might further indicate that, rather than other DC subsets, the function of MSCs treatment on the alteration of DCs in lupus patients mainly focused on CD1c+DC subtype; therefore, combining the previous results shown in the manuscript, there seemed to be more evidence to prove the causative connection between MSCs treatment and the improvement of CD1c+DCs.